(S (NP (JJ Clinical) (NN trial) (NNS registries)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VP (VB monitor) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN trial) (NN evidence))))) (CC and) (VP (NN signal) (SBAR (WHADVP (WRB when)) (S (NP (JJ systematic) (NNS reviews)) (VP (VBN become) (PP (IN out) (PP (IN of) (NP (NN date)))))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (DT this) (NN use)) (VP (VBZ has) (VP (VBN been) (VP (VBN limited) (PP (TO to) (NP (NN date))) (PP (JJ due) (TO to) (NP (NP (DT the) (JJ extensive) (JJ manual) (NN review)) (VP (VBN required) (S (VP (TO to) (VP (VP (VB search) (PP (IN for))) (CC and) (VP (JJ screen)) (NP (JJ relevant) (NN trial) (NNS registrations))))))))))) (. .))
(S (NP (PRP$ Our) (NN aim)) (VP (VBD was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT a) (JJ new) (NN method)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (ADVP (RB partially)) (VB automate) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (NN trial) (NNS registrations)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (ADJP (JJ relevant) (PP (IN for) (NP (JJ systematic) (NN review) (NNS updates)))))))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD identified) (NP (NP (CD 179) (JJ systematic) (NNS reviews)) (PP (IN of) (NP (NP (NN drug) (NNS interventions)) (PP (IN for) (NP (NN type) (CD 2) (NNS diabetes))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (NP (CD 537) (JJ clinical) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBD had) (NP (NP (NNS registrations)) (PP (IN in) (NP (NNP ClinicalTrials.gov))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD tested) (NP (NP (DT a) (NN matrix) (NN factorisation) (NN approach)) (SBAR (WHNP (WDT that)) (S (VP (VBZ uses) (NP (DT a) (JJ shared) (NN latent) (NN space)) (S (VP (TO to) (VP (VB learn) (SBAR (WHADVP (WRB how)) (S (VP (TO to) (VP (VB rank) (NP (JJ relevant) (NN trial) (NNS registrations)) (PP (IN for) (NP (DT each) (JJ systematic) (NN review)))))))))) (, ,) (S (VP (VBG comparing) (NP (DT the) (NN performance)) (S (VP (TO to) (VP (VB document) (NP (NP (NN similarity)) (SBAR (S (VP (TO to) (VP (VB rank) (NP (JJ relevant) (NN trial) (NNS registrations))))))))))))))))) (. .))
(S (NP (DT The) (CD two) (NNS approaches)) (VP (VBD were) (VP (VBN tested) (PP (IN on) (NP (NP (NP (DT a) (NN holdout) (NN set)) (PP (IN of) (NP (NP (DT the) (JJS newest) (NNS trials)) (PP (IN from) (NP (NP (DT the) (NN set)) (PP (IN of) (NP (NN type) (CD 2) (VBZ diabetes) (JJ systematic) (NNS reviews)))))))) (CC and) (NP (NP (DT an) (JJ unseen) (NN set)) (PP (IN of) (NP (NP (CD 141) (JJ clinical) (NN trial) (NNS registrations)) (PP (IN from) (NP (NP (CD 17) (JJ updated) (JJ systematic) (NNS reviews)) (VP (VBN published) (PP (IN in) (NP (NP (DT the) (NNP Cochrane) (NNP Database)) (PP (IN of) (NP (NNP Systematic) (NNP Reviews))))))))))))))) (. .))
(S (NP (DT The) (NN matrix) (NN factorisation) (NN approach)) (VP (VBD outperformed) (NP (DT the) (NN document) (NN similarity) (NN approach)) (PP (IN with) (NP (NP (NP (DT a) (JJ median) (NN rank)) (PP (IN of) (NP (CD 59)))) (CC and) (NP (NP (VB recall) (JJ @) (CD 100)) (PP (IN of) (NP (CD 60.9) (NN %)))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (DT a) (JJ median) (NN rank)) (PP (IN of) (NP (NP (CD 138)) (CC and) (NP (NP (NP (VB recall)) (JJ @) (CD 100)) (PP (IN of) (NP (CD 42.8) (NN %)))))) (PP (IN in) (NP (DT the) (NN document) (NN similarity) (NN baseline))))))) (. .))
(S (PP (IN In) (NP (NP (DT the) (JJ second) (NN set)) (PP (IN of) (NP (NP (JJ systematic) (NNS reviews)) (CC and) (NP (PRP$ their) (NNS updates)))))) (, ,) (NP (DT the) (ADJP (JJS highest) (NN performing)) (NN approach)) (VP (VP (VBN used) (NP (JJ document) (NN similarity))) (CC and) (VP (VBD gave) (NP (NP (DT a) (JJ median) (NN rank)) (PP (IN of) (NP (NP (CD 67)) (PRN (-LRB- -LRB-) (NP (VB recall) (PP (RB @) (NP (NP (CD 100)) (PP (IN of) (NP (CD 62.9) (NN %)))))) (-RRB- -RRB-))))))) (. .))
(S (NP (DT The) (VBN proposed) (NN method)) (VP (VBD was) (ADJP (JJ useful) (PP (IN for) (S (VP (VBG ranking) (NP (NN trial) (NNS registrations)) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (JJ manual) (NN workload)) (VP (VBN associated) (PP (IN with) (S (VP (VBG finding) (NP (JJ relevant) (NNS trials)) (PP (IN for) (NP (JJ systematic) (NN review) (NNS updates)))))))))))))))) (. .))
(S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN approach)) (VP (MD could) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ semi-automated) (NN pipeline)) (PP (IN for) (S (VP (VBG monitoring) (NP (ADJP (RB potentially) (JJ new)) (NN evidence)) (PP (IN for) (NP (NP (NN inclusion)) (PP (IN in) (NP (DT a) (NN review) (NN update)))))))))))))))))) (. .))
